

Supplementary Online Content

Nittala MG, Metlapally R, Ip M, et al. Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the FILLY randomized clinical trial. *JAMA Ophthalmol*. Published online February 3, 2022.
doi:10.1001/jamaophthalmol.2021.6067

eTable. Characteristics of Eyes With iRORA at Baseline

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Characteristics of Eyes With iRORA at Baseline

	Pegcetacoplan Monthly (n=18)	Pegcetacoplan Every Other Month (n=34)	Sham Injections (n=34)
GA lesion size, mean, mm ² (SD)	8.27 (4.49)	7.43 (4.13)	8.13 (4.03)
Lesion location, n (%)			
• Subfoveal	13 (72%)	22 (65%)	20 (59%)
• Nonsubfoveal	5 (28%)	12 (35%)	14 (41%)
Lesion focality, n (%)			
• Unifocal	5 (28%)	10 (29%)	6 (18%)
• Multifocal	13 (72%)	24 (71%)	28 (82%)
Presence of >5 iRORA lesions	0 (0%)	10 (29%)	3 (9%)